Built around the people
we’re treating.
Our Mission
To improve the lives of respiratory disease patients through the development of innovative inhaled therapies that address critical unmet medical needs and advance the standard of care.
A focused company with a single purpose.
AirNexis Therapeutics is a clinical-stage biotechnology company headquartered in Redwood City, California. We were founded in January 2026 with a $200 million Series A.
We are working to deliver a next-generation maintenance therapy for COPD that may provide improved efficacy and an enhanced patient experience compared to currently available treatments. We are small, focused, and moving quickly — because the people waiting on better options have waited long enough.
Our Team
AirNexis is led by an experienced team in drug development, supported by a board and advisors with deep experience building and scaling life-sciences companies.
Our Investors
